BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Regulatory & Policy
FDA Mandates Class-Wide NAION Warning for All GLP-1 Receptor Agonists: What the Labelling Change Means for Research and Procurement
The FDA has required all GLP-1 receptor agonist manufacturers — including Novo Nordisk and Eli Lilly — to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION) to their product labelling, following a meta-analysis of 126 clinical trials and two years of accumulating real-world evidence. The action extends a signal first identified with semaglutide to the entire class, including orforglipron.
10 Nov 2026
Regulatory & Policy
First Commercial Pharmacy Secures API Supply for All Six PCAC Peptides: What the Corexa Health Announcement Means for Research Procurement
DataMeds AI's subsidiary Corexa Health announced on 2 November 2026 that it has secured a commercial supply agreement for bulk drug substance and API covering all six PCAC-recommended peptides — BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax — with dispensing planned to begin this month under the HHS enforcement discretion policy. The move signals that the US compounding pharmacy market is beginning to mobilise around the October 28 policy, but formal 503A Bulks List status remains pending…
02 Nov 2026
Regulatory & Policy
HHS Issues Enforcement Discretion Policy for Six Peptides: What the 28 October Announcement Means for Research Procurement
The US Department of Health and Human Services announced on 28 October 2026 that it will not pursue enforcement action against state-licensed 503A compounding pharmacies that compound BPC-157, Epitalon, KPV, MOTS-c, Semax, or TB-500, provided strict quality and reporting conditions are met. The policy does not constitute FDA approval, does not extend to research-use-only channels, and may be withdrawn at any time — distinctions that UK research-procurement teams must keep firmly in view.
29 Oct 2026
Regulatory & Policy
Safety Group Challenges PCAC Integrity as Peptide Access Policy Sits at the White House: What the PSM Citizen Petition Means for the Regulatory Outlook
The Partnership for Safe Medicines has filed a formal citizen petition asking the FDA to block compounding of seven peptides — including BPC-157, TB-500 and Epitalon — and to disregard the July PCAC advisory vote as tainted by conflicts of interest. The petition lands while the agency's interim access policy remains under White House review, deepening the regulatory uncertainty facing research procurement teams.
25 Oct 2026
Regulatory & Policy
Peptide Interim Access Policy Enters White House Review: What the OIRA Submission and This Week's OMB Meeting Mean for Research Procurement
FDA and HHS formally submitted an "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Information and Regulatory Affairs on 14 October 2026. With the American Academy of Peptide Medicine scheduled to meet the Office of Management and Budget on 22 October, the policy has moved from internal deliberation into active White House scrutiny — though its substance, scope and timing remain publicly undisclosed.
19 Oct 2026
Regulatory & Policy
One Amino Acid, Three High Stakes: What the Seventh Circuit's Pending Retatrutide Ruling Means for Exclusivity, Medicare Pricing, and Compounding Access
The US Court of Appeals for the Seventh Circuit heard oral argument on 24 September 2026 in Eli Lilly v. FDA over whether retatrutide is legally a biologic or a drug — a question that turns on how one counts a single amino acid. The ruling, not yet published, will shape whether the triple agonist carries 5 or 12 years of exclusivity, when Medicare can negotiate its price, and whether any compounding pathway can ever lawfully exist.
12 Oct 2026
Regulatory & Policy
FDA Career Scientists Formally Oppose Administration's Interim Peptide Dispensing Plan — and What the Internal Split Means for Research Procurement
FDA drug centre staff have publicly stated they will not recommend allowing temporary compounding of unapproved peptides, placing career scientists in direct opposition to a Trump administration plan reported on 7 October 2026. The institutional fault line now visible inside the agency has immediate implications for how quickly — and through which channel — restricted peptides could re-enter legitimate supply.
11 Oct 2026
Regulatory & Policy
HHS Stopgap Plan for Restricted Peptides: What the Reported Enforcement-Discretion Proposal Means for Research Procurement
The Trump administration is reported to be crafting a stopgap that would allow certain previously restricted peptides to be sold temporarily through compounding pharmacies while formal rulemaking proceeds — a development with direct implications for research procurement, supply chain integrity, and the ongoing FDA enforcement posture on GLP-1 combination products.
09 Oct 2026
Regulatory & Policy
After the PCAC Vote: What the Six-Peptide 503A Recommendation Means in Practice — and How Long the Road to Legal Compounding Remains
The FDA's Pharmacy Compounding Advisory Committee backed BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for the 503A Bulks List in July 2026 — overriding its own staff. Three months on, legal compounding status has not changed, and formal rulemaking is expected to run at minimum eight to 24 months. This briefing maps the procedural steps still ahead and what they mean for UK research procurement.
05 Oct 2026
Regulatory & Policy
Two Months After the PCAC Vote: Where BPC-157, TB-500, Semax and Three Other Peptides Stand on the Road to the 503A Bulks List
The FDA's Pharmacy Compounding Advisory Committee recommended six peptides for 503A inclusion in July 2026 — but the votes were non-binding, FDA staff opposed all seven, and formal rulemaking has not yet begun. This briefing maps the full regulatory journey still ahead and what it means for procurement professionals today.
24 Sep 2026
Regulatory & Policy
Eight Days Left: FDA's 17 Revised Draft Peptide Guidances and What the Withdrawn 2021 Framework Means for Generic Developers
The FDA published 17 revised draft product-specific guidances for generic peptide products on 28 July 2026, covering semaglutide, tirzepatide, liraglutide, teriparatide and 13 other reference drugs. The public comment window closes on 28 September 2026 — eight days from today. The agency simultaneously withdrew its May 2021 synthetic-peptide guidance, leaving sponsors mid-programme without a replacement framework until later in 2026.
20 Sep 2026
Regulatory & Policy
After the PCAC Vote: The Three Legal Steps Between a Committee Recommendation and Lawful Peptide Compounding
The FDA's Pharmacy Compounding Advisory Committee recommended six peptides — including BPC-157, KPV, TB-500, and MOTS-c — for the 503A Bulks List in July 2026. But a committee recommendation is not compounding authorisation. This briefing maps the three distinct legal events that must follow before a pharmacy may lawfully compound these substances, and what the timeline means for UK research procurement.
10 Sep 2026